| Name | Dirithromycin |
| Description | Dirithromycin (LY237216) is a macrolide glycopeptide antibiotic. It is used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections. |
| In vivo | At therapeutic concentrations, Dirithromycin enhances the production of IL1β in cells stimulated by lipopolysaccharides, with increases of +37% and +28% at 1 μg/mL. At supra-therapeutic concentrations, Dirithromycin inhibits IL1β through the inhibition of protein kinase C; the concentration of Dirithromycin when 50% inhibition is achieved is 378 mg/mL, while for Spiramycin it is 234 mg/mL. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 2.09 mg/mL (2.5 mM), Sonication is recommended.
Ethanol : 93 mg/mL (111.37 mM), Sonication is recommended.
|
| Keywords | macrolide | LY-237216 | LY 237216 | Inhibitor | inhibit | gram-positive | Erythromycin | Dirithromycin | Bacterial | bacteria | ASE-136 | ASE136 | Antibiotic | 70S ribosome | 50S ribosome |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | EDTA copper(II) disodium salt | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Approved Drug Library | Drug Repurposing Compound Library | Microbial Natural Product Library | Anti-Bacterial Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Human Metabolite Library |
United States
